- Zacks Small Cap Research•4 months ago
Total operating expenses for the fourth quarter of 2015 were $20.1 million, compared to $3.1 million for the corresponding time period of 2014. Total operating expenses for the year ending Dec. 31, 2015 were $58.9 million, compared to $15.8 million for the year ending Dec. 31, 2014. As of Dec. 31, 2015, Pozen had cash and cash equivalents of $24.8 million.
- Zacks Small Cap Research•5 months agoARLZ: A Strong Management Team and Plenty of Capital Makes Aralez a Top Specialty Pharmaceutical Pick…
On February 5, 2015, Aralez Pharmaceuticals Inc. (ARLZ) announced that the planned merger between Pozen, Inc. and Tribute Pharmaceuticals Canada, Inc. was complete following approval by the shareholders of each company. The strategy behind Aralez is that the company will become a cardiovascular focused specialty pharmaceutical company with support from a pain-focused franchise. As a reminder, in conjunction with the completion of the merger, a group of leading healthcare investors, led by Deerfield Management, has committed up to $350 million in capital for Aralez to fund the anticipated commercial launch of YOSPRALA® and for “future acquisitions”.
TRIBUTE PHARMACEUTICOther OTC
|Day's Range||0.00 - 0.00|
|Avg Vol (3m)||N/A|
As of 3:49 PM EST. Other OTC Delayed Price. Market open.